Welcome to our dedicated page for FRESH TRACKS THERAPEUTICS news (Ticker: $FRTX), a resource for investors and traders seeking the latest updates and insights on FRESH TRACKS THERAPEUTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FRESH TRACKS THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FRESH TRACKS THERAPEUTICS's position in the market.
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. urges stockholders to vote on liquidation and dissolution plans by February 14, 2024. The Special Meeting on February 15, 2024, will seek approval for the Dissolution and Plan of Dissolution. Stockholders can participate in the virtual meeting and vote via proxy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) announced plans to hold a new special meeting of stockholders on February 15, 2024, to seek stockholder approval of the liquidation and dissolution of the Company and the plan of liquidation and dissolution. The Company intends to seek judicial dissolution if the liquidation and dissolution are not approved, which would reduce the amount of cash distributable to stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.35%
Tags
-
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) has been suspended from trading on The Nasdaq Capital Market and is now quoted on the OTC Pink market under the same trading symbol. The company has withdrawn its appeal of Nasdaq's determination to delist its common stock and intends to reconvene its special meeting of stockholders to vote on the Approval of the Liquidation and Dissolution of the Company and the Plan of Liquidation and Dissolution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (FRTX) will have its common stock suspended from trading on The Nasdaq Capital Market and will begin trading on an over-the-counter market. The company has voluntarily withdrawn its appeal to stay the suspension and delisting action, and intends to reconvene a special meeting of stockholders to vote on the approval of liquidation and dissolution of the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
-
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) has adjourned its special meeting of stockholders to December 27, 2023, and encourages all stockholders of record on October 17, 2023, who have not yet voted to do so by December 26, 2023. The company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks’ stockholders, which would reduce the amount of cash distributable to the stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) has adjourned its special meeting of stockholders to December 15, 2023, to seek approval for liquidation and dissolution. If not approved, the company intends to seek judicial dissolution, potentially reducing cash distributable to stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) Announces Adjournment of Special Meeting and Urges Stockholders to Vote on Liquidation and Dissolution Plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
-
News
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) announced a plan of liquidation and dissolution after a strategic evaluation process. The company aims to distribute between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders if the dissolution is approved at the special meeting on November 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
-
Rhea-AI Summary
Fresh Tracks Therapeutics, Inc. plans to distribute cash to shareholders between $5 million and $7 million, or $0.84 to $1.17 per share, following shareholder approval and the filing of the certificate of dissolution. The company is discontinuing all clinical and preclinical development programs and reducing its workforce, except for certain employees involved in the dissolution process. The board of directors unanimously concluded that dissolving and liquidating the company is in the best interests of shareholders. The company intends to hold a special meeting of shareholders in Q4 2023 to seek approval for the liquidation and dissolution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.17%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FRESH TRACKS THERAPEUTICS
Nasdaq:FRTX
FRTX Rankings
FRTX Stock Data
5.44M
4.83M
1.6%
17.89%
0.84%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
Boulder
About FRTX
brickell biotech, inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. our management team and board of directors has extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. our strategy is to leverage this experience to in-license, acquire, develop and commercialize products that we believe can be successful in the global dermatology marketplace. our portfolio of five product candidates, all new molecular entities with relevant mechanism of actions in skin diseases, targets significant market opportunities.